Medication Reconciliation and Management for ESRD Patient on Dialysis
Hold all additional iron supplementation immediately and obtain TSAT and TIBC before any further iron administration, as a ferritin of 1,751 ng/mL far exceeds the upper safety threshold of 800 ng/mL recommended by K/DOQI guidelines and may indicate iron overload. 1
Iron Management
Your ferritin of 1,751 ng/mL is more than double the 800 ng/mL upper limit recommended by K/DOQI guidelines 1. The guidelines explicitly state that IV iron should be withheld when ferritin exceeds 800 ng/mL or TSAT exceeds 50%, with reassessment after up to 3 months 1. While ferritin can be elevated as an acute-phase reactant in inflammation 1, 2, this level warrants immediate action:
- Confirm with the dialysis center whether the patient is receiving IV iron through dialysis sessions
- Obtain TSAT and TIBC immediately to distinguish between true iron overload (TSAT >50%) versus functional iron deficiency with inflammation (TSAT <20% despite high ferritin) 1
- Hold all IV and oral iron until these results return and nephrology reviews them
- If TSAT >50%, continue holding iron for 2-3 months, then recheck before resuming at reduced doses 1
- Recent evidence suggests ferritin >700 ng/mL may increase cardiovascular events and mortality risk in hemodialysis patients 3
Vitamin Supplementation Reconciliation
The separate folic acid 1 mg daily is likely unnecessary and should be discontinued, as Rena-Vite already contains adequate folate for dialysis patients.
Your B12 of 1,646 pg/mL (normal 200-900) and folate of 22.7 ng/mL (normal 2.7-17) are both supraphysiologic. Multiple studies demonstrate that stable dialysis patients rarely develop true folate deficiency even without supplementation 4, 5. The elevated levels result from:
- Rena-Vite (renal multivitamin) containing folic acid
- Additional folic acid 1 mg daily (duplicative)
- Reduced renal clearance of water-soluble vitamins
Action: Discontinue the separate folic acid 1 mg. Continue Rena-Vite alone, which provides adequate B-vitamin supplementation for ESRD. Recheck levels in 3 months to confirm normalization.
CKD-Mineral Bone Disease Workup
Obtain phosphorus, intact PTH, 25-hydroxyvitamin D, and GGT immediately to evaluate the alkaline phosphatase elevation of 191 U/L in the context of CKD-MBD.
The patient is already on cinacalcet (calcimimetic) and sevelamer (phosphate binder), indicating known secondary hyperparathyroidism 6, 7. Alkaline phosphatase elevation could represent:
- Bone disease: High-turnover renal osteodystrophy from uncontrolled PTH
- Hepatic disease: Less likely given medications, but GGT will differentiate
Required labs:
- Phosphorus: Target <5.5 mg/dL per K/DOQI 6
- Intact PTH: Target 150-300 pg/mL for dialysis patients 6
- 25-hydroxyvitamin D: Assess for deficiency requiring ergocalciferol
- GGT: If elevated with alkaline phosphatase, suggests hepatobiliary source
Medication management:
- Cinacalcet and vitamin D dosing should be managed by the dialysis center based on monthly PTH monitoring 6
- Sevelamer must be taken with meals; hold when patient does not eat 6
- If PTH >300 pg/mL, may need increased active vitamin D (calcitriol, paricalcitol, or doxercalciferol) 6
Glycemic Control Assessment
The A1c of 5.4% is falsely reassuring in ESRD due to shortened red cell lifespan and uremia; random glucose of 179-191 mg/dL indicates inadequate glycemic control requiring alternative monitoring.
In ESRD, A1c underestimates true glycemic burden because:
- Anemia and ESA therapy shorten RBC lifespan
- Uremic toxins carbamylate hemoglobin
- Dialysis removes glycated proteins
Actions:
- Request dialysis glucose logs from the dialysis center (pre- and post-dialysis readings)
- Consider fructosamine or glycated albumin if available (2-3 week glycemic average, not affected by RBC turnover)
- Target pre-dialysis glucose 90-150 mg/dL
- Adjust diabetes medications based on actual glucose readings, not A1c
Acid Suppression Rationalization
Reduce famotidine to 10 mg daily or 20 mg every other day immediately, as the current dose of 40 mg daily is excessive for ESRD and risks CNS toxicity including confusion and delirium. 8
Famotidine is 70% renally cleared and accumulates in ESRD. A study of ESRD patients found that most tolerated 20 mg daily well, but 3 of 38 patients developed mental status changes, suggesting individual variability 8. The 40 mg daily dose doubles the recommended maximum.
Dual acid suppression (pantoprazole + famotidine) requires justification:
- If for refractory GERD or peptic ulcer disease, continue both but adjust famotidine dose
- If no clear indication, discontinue famotidine entirely and continue pantoprazole alone (no renal adjustment needed)
- PPIs increase fracture risk in CKD-MBD patients; use lowest effective dose
Recommended famotidine dosing in ESRD:
- 10 mg daily for routine GERD
- 20 mg every other day for maintenance
- Maximum 20 mg daily for active ulcer disease
Antihistamine Duplication and Renal Adjustment
Discontinue levocetirizine (Xyzal) 5 mg daily immediately, as it is contraindicated in ESRD without dose adjustment and duplicates diphenhydramine, compounding anticholinergic burden and fall risk.
Levocetirizine is 85% renally excreted. In ESRD (CrCl <10 mL/min), it is contraindicated per FDA labeling. The current 5 mg daily dose is appropriate for normal renal function but causes excessive accumulation in dialysis patients, leading to:
- Severe sedation
- Dizziness and falls
- Urinary retention
- Cognitive impairment
Diphenhydramine 50 mg nightly also contributes to:
- Anticholinergic toxicity (confusion, constipation, urinary retention)
- Fall risk in elderly
- Paradoxical agitation
Actions:
- Stop levocetirizine immediately
- Reduce diphenhydramine to 25 mg nightly or switch to non-sedating alternative if antihistamine needed for pruritus:
- Consider gabapentin 100 mg post-dialysis three times weekly (already on for neuropathy, may help uremic pruritus)
- Avoid all first-generation antihistamines if possible in elderly ESRD patients
Metoclopramide Monitoring
Continue metoclopramide 5 mg (renally adjusted dose) but limit duration to <12 weeks and monitor closely for extrapyramidal symptoms, tardive dyskinesia, and sedation.
The 5 mg dose correctly reflects 50% reduction for ESRD. However, metoclopramide carries FDA black-box warning for tardive dyskinesia, with risk increasing with:
- Duration >12 weeks
- Elderly patients
- Renal impairment (reduced clearance)
Monitoring:
- Assess for restlessness, akathisia, dystonia, or involuntary movements at each visit
- If used for diabetic gastroparesis, consider trial discontinuation after symptom improvement
- Alternative: erythromycin 250 mg three times daily (prokinetic without extrapyramidal effects)
Lokelma Administration
Confirm dialysis center instructions for Lokelma dosing and separate administration from all other oral medications by at least 2 hours before or after. 9
Lokelma (sodium zirconium cyclosilicate) is a potassium binder that can chelate other medications in the GI tract, reducing their absorption. FDA labeling explicitly requires 2-hour separation 9.
For dialysis patients:
- Recommended starting dose: 5 g once daily on non-dialysis days only 9
- May increase to 10 g if serum K+ >6.5 mEq/L 9
- Monitor pre-dialysis K+ after long interdialytic interval
- Each 5 g dose contains ~400 mg sodium; monitor for fluid overload 9
Medication timing strategy:
- Give Lokelma at bedtime on non-dialysis days
- Take all other medications in morning and afternoon, separated by ≥2 hours
Blood Pressure Management
Do not increase antihypertensive medications based on a single reading of 141-144/67-68 mmHg; obtain pre- and post-dialysis BP readings and assess volume status with the dialysis center before any changes.
In dialysis patients, BP management is primarily volume-dependent. A single reading is insufficient because:
- Pre-dialysis BP reflects volume overload
- Post-dialysis BP reflects dry weight achievement
- Interdialytic weight gain indicates fluid retention
Actions:
- Request pre- and post-dialysis BP trends from dialysis center
- Assess interdialytic weight gain (target <2-3 kg between sessions)
- If consistently elevated pre-dialysis BP with excessive weight gain, adjust dry weight downward rather than adding medications
- If post-dialysis BP remains elevated, then consider medication adjustment
- Current diastolic of 67-68 mmHg suggests adequate control; avoid excessive lowering (risk of intradialytic hypotension)
Lactulose Indication Clarification
Clarify whether lactulose is prescribed for constipation or hepatic encephalopathy, as dosing and titration differ significantly between indications.
For constipation:
- Dose: 15-30 mL daily to twice daily
- Goal: 1-2 soft bowel movements daily
- Consider alternatives (polyethylene glycol 3350) if chronic use needed
For hepatic encephalopathy:
- Dose: 30-45 mL three to four times daily
- Goal: 2-3 soft stools daily (titrate to effect)
- Monitor for dehydration and electrolyte disturbances
- Requires ongoing liver function monitoring
If no clear indication exists, consider discontinuation and address constipation with:
- Adequate dialysate dwell time (if peritoneal dialysis)
- Increased dietary fiber if phosphorus allows
- Polyethylene glycol 3350 (no systemic absorption)
Urgent Ophthalmology Follow-Up
Schedule urgent ophthalmology evaluation within 24-48 hours for documented retinal detachment and acquired vision loss, as this represents a sight-threatening emergency requiring immediate intervention.
Retinal detachment in dialysis patients may be related to:
- Hypertensive retinopathy
- Diabetic retinopathy (if diabetic)
- Uremic retinopathy
- Rapid fluid shifts during dialysis
Delay in treatment risks permanent vision loss. Ophthalmology may recommend:
- Surgical repair (pneumatic retinopexy, scleral buckle, or vitrectomy)
- Adjustment of dialysis prescription to minimize rapid fluid shifts
- Optimization of BP and glycemic control
Summary of Immediate Actions
- Hold all iron and obtain TSAT/TIBC urgently
- Discontinue separate folic acid 1 mg (continue Rena-Vite only)
- Obtain phosphorus, intact PTH, 25-OH vitamin D, and GGT
- Reduce famotidine to 10 mg daily or discontinue if dual suppression unnecessary
- Stop levocetirizine immediately; reduce diphenhydramine to 25 mg or discontinue
- Confirm Lokelma dosing with dialysis center; ensure 2-hour medication separation
- Request dialysis glucose logs and pre/post-dialysis BP trends
- Clarify lactulose indication and adjust accordingly
- Schedule urgent ophthalmology within 24-48 hours for retinal detachment